Elsevier Inc.

SHERPA: Unknown

People

  1. Lee
    Lee
  2. Giralt
    Giralt
  3. Mulhall
    Mulhall
  4. Perales
    Perales
  5. Yorke
    Yorke
  6. Wolden
    Wolden
  7. Rusch
    Rusch
  8. Yamada
    Yamada
  9. Zhang
    Zhang
  10. Travis
    Travis

Groups

  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)
  7. Center for Hematologic Malignancies (1669)
  8. Hematologic Malignancies, Division of (1531)
  9. Sloan Kettering Institute Faculty (1376)
  10. Medical Physics (1209)
Search Within
Formats
  1. Journal Article (6733)
  2. Meeting Abstract (4312)
  3. Review (631)
  4. Book Section (542)
  5. Editorial (253)
  6. Conference Paper (132)
  7. Correspondence (92)
  8. Guidelines (85)
  9. Research Letter (33)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)

More Groups

People
  1. Nancy Lee (413)
  2. Michael Zelefsky (401)
  3. Sergio Giralt (386)
  4. John Mulhall (381)
  5. Miguel-Angel Perales (303)
  6. Andreas Rimner (292)

More People

Years
  1. 2026 (3)
  2. 2025 (397)
  3. 2024 (708)
  4. 2023 (680)
  5. 2022 (745)
  6. 2021 (665)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2629)
  2. Journal of Thoracic Oncology (973)
  3. Biology of Blood and Marrow Transplantation (815)
  4. European Journal of Cancer (529)
  5. Journal of Sexual Medicine (440)
  6. Clinical Lymphoma, Myeloma and Leukemia (402)

More Publications

Results (12842)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study
    Meeting Abstract

    Hollebecque, A.; Dotan, E.; Liao, C. Y. A.; Roda, D.; Fontana, E.; Babiker, H.; Kim, R. D.; Oh, D. Y.; Ghiringhelli, F.; Moreno, I.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens (SRs) in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 sub-analysis of black patients
    Meeting Abstract

    Patel, K. K.; Rodríguez-Otero, P.; Nooka, A. K.; Callander, N. S.; Solomon, S. R.; Baz, R.; Sborov, D. W.; Gergis, U.; Badros, A. Z.; Giralt, S. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A Multicenter, open-label phase 1/2 study of TYRA 300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301)
    Meeting Abstract

    Zhang, A.; Boni, V.; Hanson, A.; Mantia, C.; Weickhardt, A.; Yu, E.; Gupta, S.; Robert, M.; Iyer, G.; Millward, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • First clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4
    Meeting Abstract

    Yap, T. A.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S. R.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
    Meeting Abstract

    Erba, H. P.; Oluwole, O. O.; Bixby, D.; Rampal, R. K.; Fathi, A. T.; Paliwal, P.; Jin, J.; Inoue, A.; Daver, N.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Dose-optimization study of 3 starting doses of ponatinib: Long-term results from the OPTIC trial
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV): An analysis from the prospective observational study of patients with polycythemia vera in US clinical practices (REVEAL)
    Meeting Abstract

    Grunwald, M. R.; Zwicker, J. I.; Gerds, A. T.; Burke, J. M.; Xue, Z.; Crowgey, E. L.; Carl, J.; Feldman, P.; Braunstein, E. M.; Oh, S. T.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Pelabresib plus ruxolitinib combination therapy in jak inhibitor-naïve patients with myelofibrosis in the phase 3 MANIFEST-2 study: Preliminary evidence of bone marrow recovery
    Meeting Abstract

    Mascarenhas, J.; Rampal, R. K.; Vannucchi, A. M.; Gupta, V.; Oh, S. T.; Kuykendall, A. T.; Mesa, R.; Kiladjian, J. J.; Talpaz, M.; Kremyanskaya, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory CLL/SLL: Results from BTK-naïve cohort in the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Eyre, T. A.; Lech-Maranda, E.; Roeker, L. E.; Patel, M.; Fukuhara, N.; Woyach, J. A.; Brown, J. R.; Patel, K.; Tam, C. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Commentator discussion: Five-year experience with titanium mesh for rigid chest wall reconstruction
    Miscellaneous

    Tasnim, S.; Rocco, G.; Raymond, D. P.
    JTCVS Techniques (2024)

    Fulltext@MSK | Save